# Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
Canonical URL: https://biopharmsignal.com/news/IRIX/iridex-announces-new-thermal-dynamics-study-that-strengthens-clinical-foundation-and-market-potential-of-micropulser-technology-and-continuous-wave-laser-for-glaucoma-treatment
Ticker: IRIX
Company: IRIDEX
Source: IRIDEX
Published: 2025-12-08 12:00 EST
Original Source URL: https://iridex.gcs-web.com
## Summary

MOUNTAIN VIEW, Calif. , Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published

## Article Body
MOUNTAIN VIEW, Calif. , Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published
## Recent Company News
- 2026-05-19 20:05 EST — [Iridex Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/IRIX/iridex-reports-first-quarter-2026-financial-results) — Source: IRIDEX
- 2026-05-05 20:05 EST — [Iridex to Report First Quarter 2026 Financial Results on May 19, 2026](https://biopharmsignal.com/news/IRIX/iridex-to-report-first-quarter-2026-financial-results-on-may-19-2026) — Source: IRIDEX
- 2026-04-07 20:05 EST — [Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology](https://biopharmsignal.com/news/IRIX/iridex-announces-new-partnership-with-eyeprogpo-to-expand-member-access-to-retina-laser-technology) — Source: IRIDEX
- 2026-03-26 20:05 EST — [Iridex Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/IRIX/iridex-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: IRIDEX
- 2026-03-12 20:05 EST — [Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026](https://biopharmsignal.com/news/IRIX/iridex-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-26-2026) — Source: IRIDEX
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)